Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03856658 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | active not recruiting | Phase 2 | 14 | Corewell Health WestOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04263948 | Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform(MULTIDOM) | completed | N/A | 58 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 |
| clinicaltrials |
| NCT07189195 | TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma | recruiting | Phase 1 | 52 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707531 | A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer | recruiting | Early Phase 1 | 10 | Huashan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709052 | Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)(B-PDAC) | not yet recruiting | — | 180 | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05053971 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT07325214 | Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer(SonoPANIII) | not yet recruiting | N/A | 360 | IMGT Co., Ltd.INDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07704021 | Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation | completed | — | 48 | Azienda Unita Sanitaria Locale di PiacenzaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03716531 | Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement(PACER) | active not recruiting | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | active not recruiting | Phase 2 | 393 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT04469504 | Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer(PSOAS) | terminated | N/A | 6 | University Hospital, LilleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | not yet recruiting | Phase 1 | 258 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07700992 | A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring(PANXEON) | recruiting | — | 600 | Università Vita-Salute San RaffaeleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703813 | Energy Expenditure and Nutrition After Pancreatic Surgery(NUTRI-PD) | recruiting | — | 150 | Evangelismos HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05277766 | Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer(PIPAC-NAL-IRI) | active not recruiting | Phase 1 | 45 | University Hospital, GhentOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06978322 | Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer | completed | — | 50 | Minia UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT01248637 | Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole | completed | — | 200 | University Health Network, TorontoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02481635 | A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 11 | University Health Network, TorontoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04233866 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | active not recruiting | Phase 2 | 176 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05355298 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 62 | Amplia Therapeutics LimitedINDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05411094 | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors(AMPLIFY-7P) | active not recruiting | Phase 1 / Phase 2 | 158 | Elicio TherapeuticsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05908747 | Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer | completed | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07083479 | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma(AMPLIFY-EAP) | no longer available | — | — | Elicio TherapeuticsINDUSTRY | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07436741 | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer | recruiting | Phase 3 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07695532 | A Clinical Risk Score to Stratify High-risk PanNETs | completed | — | 552 | Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05415475 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | active not recruiting | Phase 2 | 24 | Bruno BockornyOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06282809 | The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy(GANNON) | recruiting | N/A | 50 | HistoSonics, Inc.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06464965 | Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer | completed | Phase 1 | 9 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07243262 | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) | recruiting | — | 6,079 | Imperial College LondonOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07612046 | A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening | recruiting | — | 79 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691593 | Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer | not yet recruiting | Phase 2 | 60 | Changhai HospitalOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07692750 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 56 | Zhejiang Cancer HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT06981273 | Robotic vs Open Pancreatoduodenectomy(SPAIN PD) | recruiting | N/A | 120 | Hospital del MarOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689539 | Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 3 | 360 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2026source: clinicaltrials